Watch Out GSK: Vectura And Hikma Target Ellipta Portfolio
Vectura and Hikma could have generic versions of GSK's Ellipta portfolio ready for marketing when patent protection expires.
You may also be interested in...
The team at Jefferies believe that the Spanish and Italian firms, as well as Hikma, are looking like good bets for the year ahead.
With a steady stream of royalties coming in from Flutiform and Ultibro and a decent pipeline of innovative respiratory drugs and generics, Vectura has presented a promising update for the year ahead.
An ambitious trial of a budesonide-based drug/device combo for uncontrolled asthma has failed, but Vectura is upbeat as it switches resources to a potential pediatric asthma treatment.